Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F24%3A43927090" target="_blank" >RIV/00216208:11120/24:43927090 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00136124 RIV/65269705:_____/24:00080016 RIV/00179906:_____/24:10481029 RIV/00064173:_____/24:43927090 RIV/00843989:_____/24:E0110998

Výsledek na webu

<a href="https://doi.org/10.1016/j.diabres.2024.111721" target="_blank" >https://doi.org/10.1016/j.diabres.2024.111721</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.diabres.2024.111721" target="_blank" >10.1016/j.diabres.2024.111721</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

Popis výsledku v původním jazyce

AIMS: Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. MATERIALS AND METHODS: Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. RESULTS: Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. CONCLUSIONS: Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.

Název v anglickém jazyce

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

Popis výsledku anglicky

AIMS: Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. MATERIALS AND METHODS: Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. RESULTS: Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. CONCLUSIONS: Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

<a href="/cs/project/TP01010040" target="_blank" >TP01010040: Podpora procesu komercializace výsledků výzkumu a vývoje na Univerzitě Karlově II</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes Research and Clinical Practice

ISSN

0168-8227

e-ISSN

1872-8227

Svazek periodika

212

Číslo periodika v rámci svazku

June

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

9

Strana od-do

111721

Kód UT WoS článku

001263613100001

EID výsledku v databázi Scopus

2-s2.0-85194579096